Risks involved in the use of stimulants for the treatment of ADHD in pregnancy
no significant concerns for teratogenicity
questionable risk of miscarriage
increased risk of prematurity
some increased risk of adverse placental outcomes (preeclampsia, abruption)
some increased risk of NICU admission and CNS disorders (seizure, NOS), etc.
data are lacking on long term neurodevelopmental effects
Risk involved in the use stimulants for the treatment of ADHD during lactation
excreted in small amounts in breast milk
due to effects on dopamine, may cause decrease in breast milk production
data are lacking on long term neurodevelopmental effects on infants
General considerations
Consider decreasing by small increments weekly when trying to taper down/off
Long acting formulations have less potential to be abused
Higher doses may increase risk for psychosis, especially with the amphetamine class
Let patients know that long acting formulations should not be crushed, cut, or chewed
The decision about whether to prescribe stimulants during the perinatal period should be made jointly with the patient after sharing information about the risks and benefits. For a good review article and demonstration of shared decision-making, please reference this article:
Baker, A. S., & Freeman, M. P. (2018). Management of Attention Deficit Hyperactivity Disorder During Pregnancy. Obstetrics and Gynecology Clinics of North America, 45(3), 495–509. https://doi.org/10.1016/j.ogc.2018.04.010